ArticleNPJ precision oncology2026
Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ameloblastomas are locally aggressive jaw tumors, primarily treated with radical surgery, which often results in significant functional and aesthetic morbidity. Innovative, personalized treatment strategies to reduce patient burden without compromising oncologic control remain lacking. This prospective observational study included comprehensive molecular profiling of 14 patients with ameloblastoma. Pathogenic mutations were identified in all cases, including alterations in BRAF, SMO, HRAS, FGFR2, and PIK3CA. Personalized treatment recommendations were made for 13 patients, and 11 received matched therapies: dabrafenib ± trametinib (n = 9), futibatinib (n = 1), or binimetinib (n = 1). Radiological tumor regression occurred in 10 of 11 treated patients. Four patients underwent surgery following neoadjuvant therapy, allowing for reduced resection extent and resulting in partial or complete pathological responses. These findings demonstrate frequent actionable alterations in ameloblastoma and clinically meaningful responses of targeted therapies. Incorporating precision oncology into standard care may facilitate personalized, less morbid surgery and improved outcomes in these rare tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.